- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Pimecrolimus Impresses
VIENNA - The ascomycin derivative pimecrolimus (ASM 981, Elidel) - currently in Phase III trials for the treatment of atopic dermatitis (topical) and psoriasis (oral) - exhibits skin-specific anti-inflammatory activity and has low potential for immunosuppression in both its topical and oral formulations.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
The Future of Pediatric Care at MOPD
Updates on Treating Warts, Molluscum Contagiosum, and Other Pediatric Conditions
A Talk with Albert Yan, MD on Current Trends in Technology
An Analysis of Gender Differences in 4645 cases of Pediatric and Adolescent Melanoma
Sneak Peek at Best Sessions on Sunday at the Society for Pediatric Dermatology Meeting
Talking with Amy Paller, MD, about the Society for Pediatric Dermatology Meeting
Acne: Therapeutic Updates and Our Most Challenging Cases
Candrice Heath, MD, Discusses Her Presentation on Atopic Dermatitis in Skin of Color
Related Content
